1-4 of 4
Shadia Jalal
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

Valentina Boni, Mary J. Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E. Sanborn, Randy F. Sweis, Patricia LoRusso, Misako Nagasaka, Javier Garcia-Corbacho, Shadia Jalal, James J. Harding, Stella K. Kim, Iris H.C. Miedema, Danielle J. Vugts, Marc C. Huisman, Gerben J.C. Zwezerijnen, Guus A.M.S. van Dongen, C. Willemien Menke van der Houven van Oordt, Song Wang, Tam Dang, Ivan A. Zein, Olga Vasiljeva, Susan K. Lyman, Virginia Paton, Alison Hannah, Joyce F. Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2020–2029.
https://doi.org/10.1158/1078-0432.CCR-21-3656
Published: 13 May 2022
View article titled, Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
Open the PDF for Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial in another window
Includes: Supplementary data
Journal Articles

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group

Allison Magnuson, Suanna S. Bruinooge, Harpreet Singh, Keith D. Wilner, Shadia Jalal, Stuart M. Lichtman, Paul G. Kluetz, Gary H. Lyman, Heidi D. Klepin, Mark E. Fleury, Brad Hirsch, Allen Melemed, Fernanda I. Arnaldez, Upal Basu Roy, Caroline Schenkel, Shimere Sherwood, Elizabeth Garrett-Mayer
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (9): 2424–2429.
https://doi.org/10.1158/1078-0432.CCR-20-3868
Published: 01 May 2021
View article titled, Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group
Open the PDF for Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group in another window
Journal Articles

Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study

Edward S. Kim, Karen Kelly, Luis G. Paz-Ares, Pilar Garrido, Shadia Jalal, Daruka Mahadevan, Martin Gutierrez, Mariano Provencio, Eric Schaefer, Monte Shaheen, Erica L. Johnston, P. Kellie Turner, Siva Rama Prasad Kambhampati, Richard Beckmann, Anwar Hossain, William J. John, Jonathan W. Goldman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (22): 5543–5551.
https://doi.org/10.1158/1078-0432.CCR-18-0651
Published: 15 November 2018
View article titled, Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study
Open the PDF for Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study in another window
Includes: Supplementary data
Journal Articles

DNA Repair: From Genome Maintenance to Biomarker and Therapeutic Target

Shadia Jalal, Jennifer N. Earley, John J. Turchi
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (22): 6973–6984.
https://doi.org/10.1158/1078-0432.CCR-11-0761
Published: 14 November 2011
View article titled, DNA Repair: From Genome Maintenance to Biomarker and Therapeutic Target
Open the PDF for DNA Repair: From Genome Maintenance to Biomarker and Therapeutic Target in another window